UCB enters agreement to acquire Candid Therapeutics in a deal worth up to $2.2 billion, adding BCMA-targeting T-cell engager ...

Announced positive ELEVATE-44-201 Cohort 1 topline results in Duchenne muscular dystrophy showing favorable safety, tolerability and early ...

First quarter 2026 total revenue was $11.1 million, up 13% over the same quarter prior yearCompany reaffirms 2026 revenue guidance of $42-44 ...

DepEd-Davao confirms the 2026-2027 school year return to the traditional June opening with a new three-term academic calendar ...

UCB has agreed to acquire Candid Therapeutics for up-to-$2.2 billion, in a deal designed to expand the buyer’s presence in ...

Thermo Fisher Scientific Inc., the world leader in serving science, today introduced the Gibco™ CTS™ DynaXS™ Single Use Bioreactor, a purpose-built expansion platform designed to help cell therapy ...

The "Preclinical Imaging Industry Analysis, Size, Share, Growth, Trends, and Forecast 2026-2033 - (by Product Type, Application, End-User, Geographic Coverage and by Company)" has been added to ...

Deal builds upon UCB’s position as a leader in immunology innovation and expands capabilities in next-generation biologics with potential for immune resetCandid’s lead asset, cizutamig, a bispecific ...

UCB, a global biopharmaceutical company, today (May 3rd) announced signing of a definitive agreement under which it would ...

UCB to buy clinical-stage biotech company, Candid Therapeuticsfor US$ 2.2 billion: Brussels, Belgium Tuesday, May 5, 2026, 09:00 Hrs [IST] UCB, a global biopharmaceutical company, ...

Global stock markets posted strong gains through mid-April, driven by optimism surrounding a near-term and favorable ...